FINWIRES · TerminalLIVE
FINWIRES

HKG:1477

5 stories mentioning HKG:1477Updated just now

Every FINWIRES story that references HKG:1477, newest first.

What's the latest news on HKG:1477?

Asia

Ocumension's NDA For Ocular Treatment Approved in China

Ocumension Therapeutics (HKG:1477) said Friday that the Chinese healthcare regulator approved its new drug application for OT-301, its proposed treatment for glaucoma or ocular hypertension-related complications, according to a same-day bourse filing.The pharmaceutical company said the approval follows the completion of the Mont Blanc and Denali trials of OT-301, in which the treatment achieved key study goals.The company's shares are down 2.8% in afternoon trading on the HKEX.

HKG:1477
Asia

Ocumension Therapeutics' Application for Ocular Inflammation Drug Accepted in China

Ocumension Therapeutics' (HKG:1477) application for the registration of dexamethasone intraocular suspension was accepted by China's National Medical Products Administration.The product is indicated for the treatment of postoperative ocular inflammation, according to a Tuesday Hong Kong bourse filing.

HKG:1477
Asia

Ocumension Therapeutics Enrolls First Patient in Dry Eye Drug Study

Ocumension Therapeutics (HKG:1477) enrolled the first patient in a phase III clinical trial of OT-202.The trial is studying the drug for the treatment of dry eye disease in China, according to a Monday Hong Kong bourse filing.

HKG:1477
Asia

Ocumension Therapeutics Wins China Nod for Eye Inflammation Drug

Ocumension Therapeutics (HKG:1477) received approval from China's National Medical Products Administration for the new drug application of OT-502, according to a Thursday Hong Kong bourse filing.OT-502, marketed as DEXYCU and Shishu, is a single-dose, sustained-release dexamethasone intraocular suspension indicated for the treatment of postoperative ocular inflammation.

HKG:1477
Asia

Ocumension Therapeutics Enrolls First Patient in Presbyopia Drug Trial

Ocumension Therapeutics (HKG:1477) enrolled the first patient in a phase III clinical trial of OT-802 (pilocarpine hydrochloride) in China, according to a Thursday Hong Kong bourse filing.The drug has been developed for the treatment of presbyopia, the ophthalmic pharmaceuticals maker said.

HKG:1477

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:1477 in your portfolio
WheelAI
WheelAI
Analyze HKG:1477 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:1477